Latest Conference Articles
How CTCL Treatment Strategies Have Changed, Advanced in Recent Years
September 24th 2021, 12:00pm
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.
Overview of Recent Key Trials in the CTCL Space
September 23rd 2021, 12:00pm
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.
Understanding the Patient Selection Process for CTCL Treatment
September 22nd 2021, 12:00pm
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.
Overview of Treatment Approaches in Advanced CTCL
September 21st 2021, 4:09pm
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.
Salvage Therapy for Amyloidosis in Multiple Myeloma: Agents and Anti-Fibril Therapy
September 17th 2021, 5:29pm
A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma.
Updates in Sequencing Treatment for Early Multiple Myeloma Relapse
September 15th 2021, 7:42pm
Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.
Balancing Toxicity, Tolerability, Efficacy Is Essential for CAR T-Cell Therapies in Indolent B-Cell Lymphoma
September 10th 2021, 6:53pm
With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases
Investigational BTK Inhibitor Shows Promise in Chronic, Small Lymphocytic Leukemia
September 9th 2021, 8:10pm
The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.
Understanding and Overcoming Toxicities in Asparaginase Treatment for ALL
September 9th 2021, 4:50pm
Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.